These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 31629725)

  • 21. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
    Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
    Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.
    Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
    Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
    N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
    Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F
    Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of different doses of anthracyclines combined with arsenic trioxide and all-trans retinoic acid in the treatment of de novo acute promyelocytic leukemia.
    Wu Y; Ke P; Zhou H; Wu D; Chen S; Qiu H; Han Y; Li C; Ma X; Sun A; Tang X; Hu X
    Hematology; 2021 Dec; 26(1):271-276. PubMed ID: 33631089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superiority of anthracycline-free treatment in standard-risk acute promyelocytic leukemia: A systematic review and comparative epidemiological analysis.
    Langdon K; Cosentino S; Wawryk O
    Cancer Rep (Hoboken); 2024 Mar; 7(3):e2035. PubMed ID: 38507294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.
    Long ZJ; Hu Y; Li XD; He Y; Xiao RZ; Fang ZG; Wang DN; Liu JJ; Yan JS; Huang RW; Lin DJ; Liu Q
    PLoS One; 2014; 9(8):e104610. PubMed ID: 25122165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.
    Xu LW; Su YZ; Tao HF
    Curr Med Sci; 2021 Jun; 41(3):491-497. PubMed ID: 34169421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL).
    Gupta V; Yi QL; Brandwein J; Lipton JH; Messner HA; Schuh AC; Wells RA; Minden MD
    Leuk Res; 2005 Jan; 29(1):113-4. PubMed ID: 15541484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Leuk Res; 2013 Jan; 37(1):37-42. PubMed ID: 23017225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.
    Gore SD; Gojo I; Sekeres MA; Morris L; Devetten M; Jamieson K; Redner RL; Arceci R; Owoeye I; Dauses T; Schachter-Tokarz E; Gallagher RE
    J Clin Oncol; 2010 Feb; 28(6):1047-53. PubMed ID: 20085935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
    Wang H; Chen XY; Wang BS; Rong ZX; Qi H; Chen HZ
    Leuk Res; 2011 Sep; 35(9):1170-7. PubMed ID: 21774985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia.
    Sasaki K; Ravandi F; Kadia T; DiNardo CD; Yilmaz M; Short N; Jabbour E; Patel KP; Loghavi S; Pierce S; Borthakur G; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):375-381. PubMed ID: 38431521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study.
    Gill H; Kumana CR; Yim R; Hwang YY; Chan TSY; Yip SF; Lee HKK; Mak V; Lau JSM; Chan CC; Kho B; Wong RSM; Li W; Lin SY; Lau CK; Ip HW; Leung RYY; Lam CCK; Kwong YL
    Cancer; 2019 Sep; 125(17):3001-3012. PubMed ID: 31090936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).
    Kutny MA; Geyer S; Laumann KM; Gregory J; Willman CL; Stock W; Larson RA; Powell BL; Feusner JH
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27542. PubMed ID: 30393935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful Treatment With ATRA and Arsenic Trioxide for a Child With Down Syndrome and Acute Promyelocytic Leukemia.
    Tsumura Y; Yamada Y; Osumi T; Kato M; Terashima K; Shioda Y; Kiyotani C; Matsumoto K; Tomizawa D
    J Pediatr Hematol Oncol; 2020 May; 42(4):322-325. PubMed ID: 30807394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study.
    Au WY; Kumana CR; Lee HK; Lin SY; Liu H; Yeung DY; Lau JS; Kwong YL
    Blood; 2011 Dec; 118(25):6535-43. PubMed ID: 21998212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.